Dr. Anny SHEN
Nanjing Medical University and Wuhan Medical University
Title: Marketing Analyses on Inhalation Products for Anti-Asthma and COPD in China
Biography:
Dr. Anny SHEN
Managing Director of Bering Scientific Information Ltd, Nanjing China.
Completed her studies at Nanjing Medical University and Wuhan Medical University.
She has 8 years clinical medicine experience working in hospitals specializing in respiratory diseases and has more than 20 years’ experience with international pharmaceutical companies – 5 years at GSK working in clinical research for inhaled products and 14 years at Aptar Pharma, working in pharmaceutical sales and business development and the marketing research of MDIs for asthma and COPD.
Dr. Anny Shen has experience in inhaled device and inhaled drug package and regulated affairs.
She received training and study on FDA / EMA regulator of inhalation products and USP / Ph.Eur for inhalation products.
Since 2011, she started a new challenge to concentrate on Asthma and COPD market research in China and training on inhalation drug regulations, (FDA, EMA, CFDA) pharmacopeia standard, quality, and BE study…
She is also working as a senior consultant for the China inhalation industry.
Dr. Anny Shen is a director of the Inhalation Asia conference organization and a Chairman of the Inhalation Drug Delivery Association（IDDA)
Abstract:
A summary of Asthma and COPD and epidemiological characteristics
Mainland China has a total population of 1.4 billion. The increase of population in Chinese cities, large number of people smoking cigarettes (>300 million smokers and > 150million people suffering from second hand smoking), use of motor cars, rapid industrial expansion and worsening environmental pollution are major causes of human respiratory diseases.
Asthma : There were over 60 million asthma patients in 2019. 0-14 years children’s prevalence has risen by 148% in 20 years in big cities.
COPD: Incidence of COPD is very high in China and there were 100 million patients in 2019.
The incidence of COPD among smokers was 13.7%. It has more than double the prevalence of non smokers.
The incidence of COPD was > 40% for smokers over 60 years of age
The incidence of COPD was 25 % for smokers over 40 years of age.